Drugs / Atiprimod
Atiprimod
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | plasma cell myeloma | 2003-09-23 | “Callisto filed an IND on September 23, 2003 with the U.S. Food and Drug Administration on Atiprimod” callistopharma.com ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00430014 | Mar 2005 → Feb 2012 | cancer of unknown primary site | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00214838 | Mar 2005 → Mar 2007 | — | Callisto Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00086216 | May 2004 → Nov 2007 | plasma cell myeloma | Callisto Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00663429 | Nov 2007 → Mar 2010 | neuroendocrine carcinoma | Callisto Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00388063 | Oct 2006 → Sep 2007 | neuroendocrine carcinoma | Callisto Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2007-04-11 | Callisto Pharmaceuticals | Results Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma Article Published in Recent Issue of Journal Blood callistopharma.com ↗
The animal data demonstrated that Atiprimod significantly inhibited tumor growth in vivo and prolonged survival of tumor-bearing mice. |
| 2004-01-06 | Callisto Pharmaceuticals | Regulatory CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ATIPRIMOD FOR MULTIPLE MYELOMA INDICATION callistopharma.com ↗ |
| 2003-12-12 | Callisto Pharmaceuticals | Results RESEARCH PRESENTED ON CALLISTO PHARMACEUTICALS’ LEAD DRUG CANDIDATE FOR MULTIPLE MYELOMA callistopharma.com ↗
Atiprimod is shown to affect the activation of a key signaling enzyme in multiple myeloma cells needed to support cancer cell growth. |
| 2003-11-25 | Callisto Pharmaceuticals | Results Callisto Pharmaceuticals Presents Preclinical Findings on Its Lead Drug Candidate for Multiple Myeloma callistopharma.com ↗
Further, the compound has been shown to inhibit both cancer cell migration and angiogenesis — the process that grows blood vessels to supply oxygen and nutrients to tumor cells. |
| 2003-09-24 | Callisto Pharmaceuticals | Regulatory CALLISTO PHARMACEUTICALS ANNOUNCES FILING OF IND ON ATIPRIMOD FOR MULTIPLE MYELOMA callistopharma.com ↗
Callisto Pharmaceuticals, Inc. (OTCBB: CLSP ) today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its cancer drug Atiprimod . |
All press releases naming this drug 13 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atiprimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00214838 ↗ |
| Known as | ATIPRIMOD DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL103735 ↗ |
| Known as | SK&F 106615-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL103735 ↗ |
| Known as | SK&F 106615-A2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL103735 ↗ |
| Known as | SK&F-106615 | ChEMBL registry synonym — accepted as the source's own label CHEMBL103735 ↗ |
| Modality | Small molecule | — CHEMBL103735 ↗ |
| Route | Oral | “to be given orally” NCT00086216 ↗ |